> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# IRS Now Seeks Penalties From Amgen For 2016-2018, Echoing A $2.0 Billion Claim For Earlier Years
- URL: https://www.bullished.co/irs-now-seeks-penalties-from-amgen-for-2016-2018-echoing-a-2-0-billion-claim-for-earlier-234244a4/
- Published: 2026-11-04T11:11:11.000Z
- Updated: 2026-11-04T11:11:11.000Z
- Description: Amgen says it will contest a September draft IRS notice, while a Tax Court ruling on 2010-2015 is expected no earlier than late 2026 or early 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, AMGN, Industry: Healthcare

[Amgen](https://www.bullished.co/tag/amgn/), the biotech drugmaker behind Repatha, Otezla and ENBREL, said in its [quarterly report](https://www.sec.gov/Archives/edgar/data/0000318154/000031815426000155/amgn-20260930.htm?ref=bullished.co) that the IRS sent a draft notice in September asserting penalties for 2016-2018 that are substantially similar to those it asserted for 2013-2015\. Amgen disagrees and intends to contest them.

## A third audit period draws penalties

The September draft notice of proposed adjustment covers 2016-2018\. Amgen says that if sustained in full, the adjustments and penalties "could have a material impact on our financial statements."

The [prior quarterly filing](https://www.sec.gov/Archives/edgar/data/0000318154/000031815426000126/amgn-20260630.htm?ref=bullished.co) discussed only the earlier notice for those years, which arrived in April and was reissued in May and July in substantially the same form. The new draft adds penalties on top of it.

Amgen has told the IRS audit team that its methodology conflicts with positions the IRS took in Tax Court, which were more favorable to Amgen than those the audit team had taken.

## The $2.0 billion template

The 2013-2015 notice seeks about $5.1 billion in additional federal tax plus interest and asserts penalties of about $2.0 billion. Amgen is contesting it in U.S. Tax Court, and says any extra tax would be reduced by up to about $2.2 billion of repatriation tax it already paid.

The dispute centers on how Amgen allocates profits between its U.S. entities and its operations in Puerto Rico. The 2010-2012 notices seek about $3.6 billion in additional tax plus interest, reducible by up to about $900 million of repatriation tax. Amgen says it firmly believes the IRS positions for 2010-2015 are without merit.

The IRS began auditing 2019-2022 in the second quarter of 2026, and Amgen believes it may pursue similar issues there.

## Waiting on the Tax Court

The 2010-2012 and 2013-2015 cases were consolidated, with trial running from November 4, 2024 to January 17, 2025\. Supplemental closing briefs were filed on May 20, 2026\. Amgen expects a decision no earlier than late 2026 or early 2027.

Final resolution of its tax matters is not likely within the next 12 months, the company says. It adds that outcomes could mean payments substantially greater than it has accrued.

The tax fight sits against solid results. Total revenues rose 8% to $10,365 million in the third quarter, and net income reached $3,864 million, up from $3,216 million a year earlier, the filing shows. Amgen sells medicines for serious diseases and reports one segment, human therapeutics.

## Another asset under watch

Separately, the filing carries the U.S. TAVNEOS developed-product rights at $2.2 billion as of September 30, 2026\. Amgen says future drops in estimated cash flows could leave that value unrecoverable.

The FDA's drug center proposed in April to withdraw approval of TAVNEOS. Amgen requested a hearing and submitted data in July, and says the agency has not yet responded.

The Tax Court's ruling on 2010-2015, expected no earlier than late 2026 or early 2027, will be the first answer on the IRS positions Amgen is now facing for 2016-2018.

### Sources

- [10-Q Filing — Amgen (AMGN)](https://www.sec.gov/Archives/edgar/data/0000318154/000031815426000155/amgn-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Amgen (AMGN), Q2 FY2026 filed 2026-08-05 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000318154/000031815426000126/amgn-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, amgn-20260930earningsrelea.htm) — Amgen, filed 2026-11-03](https://www.sec.gov/Archives/edgar/data/0000318154/000031815426000153/amgn-20260930earningsrelea.htm?ref=bullished.co) — SEC EDGAR

### More on Amgen

- [Amgen Says Imdeltra Lung Cancer Results Are 'Difficult To Overstate' As It Raises 2026 Guidance](https://www.bullished.co/amgen-says-imdeltra-lung-cancer-results-are-difficult-to-overstate-as-it-raises-2026-98283e39/)
- [Amgen's Repatha Jumps 37% And Evenity 39%, Outrunning Prolia's 45% Biosimilar Drop](https://www.bullished.co/amgens-repatha-jumps-37-and-evenity-39-outrunning-prolias-45-biosimilar-drop-795da9d7/)
- [FDA Says Amgen's Vectibix Video Pitched Speed And Skipped Every Risk](https://www.bullished.co/fda-says-amgens-vectibix-video-pitched-speed-and-skipped-every-risk-cfcafbb6/)

[All Amgen (AMGN) coverage →](https://www.bullished.co/tag/amgn/)